EXICURE, INC. Research and Development Expense
EXICURE, INC. (XCUR) reported Research and Development Expense of $174.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- EXICURE, INC. research and development expense for the quarter ending 2026-06-30 was $174.00K, a 81.39% decline year-over-year.
- EXICURE, INC. research and development expense for the quarter ending 2026-03-31 was $312.00K, a 61.39% decline year-over-year.
- EXICURE, INC. research and development expense for the quarter ending 2025-12-31 was $655.00K.
- EXICURE, INC. research and development expense for the quarter ending 2025-09-30 was $888.00K.
- EXICURE, INC. research and development expense for fiscal 2025 was $3.29M.
- EXICURE, INC. research and development expense for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- EXICURE, INC. research and development expense for fiscal 2023 was $1.42M, a 92.80% decline from fiscal 2022.
- EXICURE, INC. research and development expense for fiscal 2022 was $19.77M, a 59.64% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $174.00K 10-Q · filed 2026-08-14 | $486.00K 10-Q · filed 2026-08-14 | $1.14M derived: sum of 3 quarters · filed 2026-08-14 | $2.03M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $312.00K 10-Q · filed 2026-05-29 | $967.00K derived: sum of 2 quarters · filed 2026-05-29 | $1.85M derived: sum of 3 quarters · filed 2026-05-29 | $2.79M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | $655.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.54M derived: sum of 2 quarters · filed 2026-03-25 | $2.48M derived: sum of 3 quarters · filed 2026-08-14 | $3.29M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $888.00K 10-Q · filed 2025-11-07 | $1.82M derived: sum of 2 quarters · filed 2026-08-14 | $2.63M 10-Q · filed 2025-11-07 | $2.63M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | $935.00K 10-Q · filed 2026-08-14 | $1.74M 10-Q · filed 2026-08-14 | $1.74M derived: sum of 3 quarters · filed 2026-08-14 | $1.74M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | $808.00K 10-Q · filed 2026-05-29 | $808.00K derived: sum of 2 quarters · filed 2026-05-29 | $808.00K derived: sum of 3 quarters · filed 2026-05-29 | $808.00K derived: sum of 4 quarters · filed 2026-05-29 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 derived: sum of 3 quarters · filed 2026-03-25 | $0.00 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 4 quarters · filed 2025-11-07 | ||||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-08 | $0.00 10-Q · filed 2025-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-08-08 | $0.00 derived: sum of 4 quarters · filed 2025-08-08 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2025-06-27 | $0.00 derived: sum of 2 quarters · filed 2025-06-27 | $0.00 derived: sum of 3 quarters · filed 2025-06-27 | $0.00 derived: sum of 4 quarters · filed 2025-06-27 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $0.00 derived: sum of 2 quarters · filed 2025-03-18 | $0.00 derived: sum of 3 quarters · filed 2025-03-18 | $1.42M 10-K · filed 2025-03-18 | ||||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $1.42M 10-Q · filed 2024-11-14 | $2.50M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 | $921.00K 10-Q · filed 2023-08-11 | $1.42M 10-Q · filed 2024-08-13 | $2.90M 10-Q · filed 2023-08-11 | $2.50M derived: sum of 3 quarters · filed 2024-08-13 | $7.30M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $1.42M 10-Q · filed 2024-06-17 | $1.98M 10-Q · filed 2023-07-14 | $2.50M derived: sum of 2 quarters · filed 2024-06-17 | $7.30M derived: sum of 3 quarters · filed 2024-06-17 | $14.05M derived: sum of 4 quarters · filed 2024-06-17 | |||
| 2022-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-06 | $5.88M derived: sum of 2 quarters · filed 2024-06-06 | $12.63M derived: sum of 3 quarters · filed 2024-06-06 | $19.77M 10-K · filed 2024-06-06 | ||||
| 2022-09-30 | $4.80M 10-Q · filed 2024-05-16 | $11.55M derived: sum of 2 quarters · filed 2024-06-06 | $18.69M 10-Q · filed 2024-05-16 | $30.11M derived: sum of 4 quarters · filed 2024-06-06 | ||||
| 2022-06-30 | $6.75M 10-Q/A · filed 2024-06-06 | $13.89M 10-Q/A · filed 2024-06-06 | $25.31M derived: sum of 3 quarters · filed 2024-06-06 | $41.76M derived: sum of 4 quarters · filed 2024-06-06 | ||||
| 2022-03-31 | $7.14M 10-Q/A · filed 2024-06-06 | $18.56M derived: sum of 2 quarters · filed 2024-06-06 | $35.01M derived: sum of 3 quarters · filed 2024-06-06 | $45.86M derived: sum of 4 quarters · filed 2024-06-06 | ||||
| 2021-12-31 | $11.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $27.87M derived: sum of 2 quarters · filed 2023-03-27 | $38.72M derived: sum of 3 quarters · filed 2023-03-27 | $48.98M 10-K · filed 2023-03-27 | ||||
| 2021-09-30 | $16.46M 10-Q · filed 2022-11-14 | $27.30M derived: sum of 2 quarters · filed 2022-11-14 | $37.56M 10-Q · filed 2022-11-14 | $47.43M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $10.84M 10-Q · filed 2022-08-15 | $21.11M 10-Q · filed 2022-08-15 | $30.98M derived: sum of 3 quarters · filed 2022-08-15 | $40.12M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $10.26M 10-Q · filed 2022-05-16 | $20.13M derived: sum of 2 quarters · filed 2022-05-16 | $29.27M derived: sum of 3 quarters · filed 2022-05-16 | $36.28M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $9.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $19.01M derived: sum of 2 quarters · filed 2022-03-25 | $26.02M derived: sum of 3 quarters · filed 2022-03-25 | $32.09M 10-K · filed 2022-03-25 | ||||
| 2020-09-30 | $9.14M 10-Q · filed 2021-11-19 | $16.15M derived: sum of 2 quarters · filed 2021-11-19 | $22.22M 10-Q · filed 2021-11-19 | $30.49M derived: sum of 4 quarters · filed 2021-11-19 | ||||
| 2020-06-30 | $7.01M 10-Q · filed 2021-08-12 | $13.08M 10-Q · filed 2021-08-12 | $21.35M derived: sum of 3 quarters · filed 2021-08-12 | $25.59M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $6.08M 10-Q · filed 2021-05-12 | $14.34M derived: sum of 2 quarters · filed 2021-05-12 | $18.59M derived: sum of 3 quarters · filed 2021-05-12 | $22.02M derived: sum of 4 quarters · filed 2021-05-12 | ||||
| 2019-12-31 | $8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $12.51M derived: sum of 2 quarters · filed 2021-03-11 | $15.95M derived: sum of 3 quarters · filed 2021-03-11 | $19.34M 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | $4.25M 10-Q · filed 2020-11-12 | $7.68M derived: sum of 2 quarters · filed 2020-11-12 | $11.07M 10-Q · filed 2020-11-12 | $14.08M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | $3.43M 10-Q · filed 2020-08-12 | $6.83M 10-Q · filed 2020-08-12 | $9.84M derived: sum of 3 quarters · filed 2020-08-12 | $13.84M derived: sum of 4 quarters · filed 2020-08-12 | ||||
| 2019-03-31 | $3.40M 10-Q · filed 2020-05-14 | $6.40M derived: sum of 2 quarters · filed 2020-05-14 | $10.40M derived: sum of 3 quarters · filed 2020-05-14 | $14.24M derived: sum of 4 quarters · filed 2020-05-14 | ||||
| 2018-12-31 | $3.01M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $7.01M derived: sum of 2 quarters · filed 2020-03-10 | $10.84M derived: sum of 3 quarters · filed 2020-03-10 | $14.12M 10-K · filed 2020-03-10 | ||||
| 2018-09-30 | $4.00M 10-Q · filed 2019-11-07 | $7.84M derived: sum of 2 quarters · filed 2019-11-07 | $11.11M 10-Q · filed 2019-11-07 | $14.28M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | $3.83M 10-Q · filed 2019-08-08 | $7.11M 10-Q · filed 2019-08-08 | $10.28M derived: sum of 3 quarters · filed 2019-09-23 | $13.40M derived: sum of 4 quarters · filed 2019-09-23 | ||||
| 2018-03-31 | $3.27M 10-Q · filed 2019-05-08 | $6.45M derived: sum of 2 quarters · filed 2019-09-23 | $9.57M derived: sum of 3 quarters · filed 2019-09-23 | $12.87M derived: sum of 4 quarters · filed 2019-09-23 | ||||
| 2017-12-31 | $3.17M derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-09-23 | $6.29M derived: sum of 2 quarters · filed 2019-09-23 | $9.59M derived: sum of 3 quarters · filed 2019-09-23 | $13.08M 10-K/A · filed 2019-09-23 | $14.11M 10-K · filed 2018-03-09 | |||
| 2017-09-30 | $3.12M 10-Q · filed 2018-11-06 | $3.50M 10-Q · filed 2017-11-14 | $6.42M derived: sum of 2 quarters · filed 2018-11-06 | $9.91M 10-Q · filed 2018-11-06 | $11.28M 10-Q · filed 2017-11-14 | $15.24M derived: sum of 4 quarters · filed 2018-11-06 | ||
| 2017-06-30 | $3.30M 10-Q · filed 2018-08-06 | $6.79M 10-Q · filed 2018-08-06 | $12.12M derived: sum of 3 quarters · filed 2018-08-06 | $14.53M derived: sum of 4 quarters · filed 2018-08-06 | ||||
| 2017-03-31 | $3.49M 10-Q · filed 2018-05-15 | $8.82M derived: sum of 2 quarters · filed 2018-05-15 | $11.23M derived: sum of 3 quarters · filed 2018-05-15 | |||||
| 2016-12-31 | $5.33M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $7.74M derived: sum of 2 quarters · filed 2018-03-09 | $13.66M 10-K · filed 2018-03-09 | |||||
| 2016-09-30 | $2.41M 10-Q · filed 2017-11-14 | $8.33M 10-Q · filed 2017-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |